Ozempic calculator

It shows an estimated medication level over time, based on your dose schedule and the half-life published on the drug label. The line rises after a dose, peaks, then falls until the next one. It is a picture of the pattern, not a reading from your body.

No. A blood test measures what is in you right now. This is arithmetic applied to a published average, so it cannot know your absorption, your kidney function or anything else specific to you. Treat it as educational.

The half-life is the time it takes for half of the drug to leave your body. For semaglutide it is about 7 days, so roughly half of a dose is still there a week later. That single number is what gives each medication its shape on the chart.

With a half-life of about 7 days, about half remains after one week, about a quarter after two, and about an eighth after three. Most of a dose is gone after roughly five half-lives, which works out to about five weeks.

About 5 days. The Mounjaro label prints that figure and the overdosage section of the Zepbound label repeats it, while the Zepbound pharmacokinetics section gives about 5 to 6 days for the same molecule measured in adults with overweight or obesity. Following the same five half-life rule, a dose is largely cleared after roughly four weeks.

Steady state is the point where the amount you take each week matches the amount you clear each week, so the line stops drifting upward and just repeats. It takes about four to five half-lives, which is around four to five weeks for semaglutide and about four weeks for tirzepatide.

Because a week is about one half-life for these drugs, so a new dose lands on top of a substantial leftover from the previous one. That stacking continues until clearance catches up with intake, which is exactly what steady state means. Nothing has gone wrong, and it is not a reason to change anything.

The drug has to be absorbed from the injection site before it reaches its highest level, and that absorption is slow with these medications. The model uses an absorption half-life of about 2 days for the weekly injectables, which is what puts the estimated peak in the first days after the dose rather than on the day itself.

Day 2 comes up often in what people report, and it is close to where the estimated level peaks on a weekly injection, so the two are frequently mentioned together. That is a pattern people describe, not a rule about your body. Some people notice day 1, some notice day 3, and some notice nothing in particular.

No. It models a medication level and nothing else. Side effects depend on the drug, the dose, how long you have been on it and a great deal about you that no chart can see. If you want to find your own pattern, log how you feel against the day of your cycle and look at what actually repeats.

No. This tool gives you no basis for changing, splitting, skipping, delaying or doubling anything, and it is not built to. Dose decisions belong to you and your prescriber, with your full history in the room.

The line dips a little lower before the next dose lifts it again, and the dip is more visible with tirzepatide than with semaglutide because it clears faster. The chart lets you see the shape of a late dose. What to do about a late dose is a question for your prescriber, and the answer is on your medication label.

The estimated level falls for two weeks instead of one, so with semaglutide it lands somewhere near a quarter of where it started, and with tirzepatide it drops further. When you resume, the line climbs back over the following weeks. Follow your label and your prescriber on missed doses, never this chart.

Semaglutide clears more slowly (about 7 days versus about 5), so its line is flatter between doses and takes a little longer to settle. Tirzepatide shows a more noticeable rise and fall each week. They are also different molecules working on different receptors, and the chart says nothing about which suits anyone.

They are the same molecule with different labels, so this calculator draws both with the same half-life of about 5 days and the two curves are identical. That is the figure the Mounjaro label prints and the Zepbound label repeats in its overdosage section. The Zepbound pharmacokinetics section words it as about 5 to 6 days because it was measured in adults with overweight or obesity, so read the curve as a band of roughly that width rather than a single line.

The whole line shifts to a higher level and then climbs again for several weeks until it settles at a new steady pattern. The shape stays the same, the scale changes. When and whether to move up is entirely between you and your prescriber.

Yes, and it is a much flatter one. Oral semaglutide (Rybelsus, Wegovy tablets) has the same 7 day half-life as the injection, but taking a smaller amount every day instead of one weekly dose smooths out the peaks and troughs. Orforglipron (Foundayo) has a published half-life given as a range of about 29 to 49 hours, roughly 1.2 to 2.0 days, so its line is drawn as a wider estimate.

Very. Saxenda and Victoza have a half-life of about 13 hours, so the level rises and falls within a single day and almost nothing carries into the next week. A missed day shows up on the chart immediately, which is not the case for weekly medications.

Only as a rough sketch. Retatrutide is not FDA approved and has no approved dose, and the figure of about 6 days comes from a phase 1b trial rather than a label. Anything drawn from a number like that should be read as provisional.

In your body, almost certainly. In this model, no. It uses population figures from published labels and applies them the same way for everyone, which is the honest limitation of any calculator that does not draw your blood.

This model does not treat sites differently, so the chart looks the same whether you use your abdomen, thigh or arm. Rotating sites still matters for your skin and for comfort, which is why the Setva app keeps track of where each shot went.

Because a percentage is the part that is actually meaningful here. The chart compares today against the steady peak of your own dose, which shows you where you sit in the week. A concentration figure would look precise and would not be, since the model has no measurement of you.

Nowhere. Everything is calculated in your browser, nothing you type is sent to Setva, and your answers are not added to the URL. Close the tab and it is gone.

No. The calculator is free and complete without either. The email box at the end exists only if you want the chart as a PDF, a reminder before your next dose or a note when the app launches, and you can use the tool and leave without touching it.

You can, and the more useful thing to bring is your own log: the dates you dosed and what you noticed on which day. The curve is a teaching picture built from label averages, so it explains the shape of the week rather than telling anyone anything about you.

Then it is not here, and we would rather leave it out than draw a line from a number we cannot source. Setva only charts drugs with a half-life published on an FDA label, plus retatrutide, which is clearly marked as preliminary.

An iPhone app for tracking GLP-1 treatment: doses, injection sites, side effects by day of the cycle, weight, and this curve on your home screen and your watch. Your health data stays on your iPhone and in your private iCloud, with no accounts and no server of ours.

Not yet. Setva is on its way to the App Store and is not available to install. Leave your email above and you will hear the day it goes live. It will cost 79.99 USD a year or 12.99 USD a week, with no trial.